CSIR- CCMB develops perhaps 1st specific drug for COVID-19 treatment
The CSIR- Centre for Mobile and Molecular Biology has created, maybe the to start with specific drug for COVID-19 treatment, which comprise therapeutic antibodies.
The Drug Controller Standard of India (DGCI) has presented its acceptance for human trials, Stage-I and Phase-II for the VINCOV-19 and envisioned to be tried following week in Delhi and Rajasthan.
Designed by the CCMB, College of Hyderabad and Vins Bioproduct ltd blend, the VINCOV-19 is a assortment of antibodies from Horses after they received injected inactivated Corona virus.
CCMB Director Dr Rakesh K Mishra knowledgeable our Hyderabad correspondent that the acceptance for its emergency use by the India’s Drug Regulator is expected as soon as the benefits of phase I and II declared.
He exuded confidence that it may possibly consider 3-4 weeks for getting acceptance for unexpected emergency use.
He even further stated the VINCOV could be the to start with certain drug for COVID treatment method and it functions very best when offered on early stage of infection.